Medicare beneficiaries in some parts of the United States appear more likely to receive carotid endarterectomy, a surgical procedure to clear blockages in the artery supplying blood to the head, whereas those in other regions more often receive stents for the same condition, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
According to the National Alliance for Caregiving, more than 65 million people in the United States serve as informal caregivers, typically for family members, which equates to more than one out of every four people serving as unpaid caregivers.
Ingen Technologies, Inc. (Pink Sheets:IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company has also filed a U.S patent and will begin the required manufacturing processes to produce the new drug insulin thermos product.
Research shows behavioral economic analysis may help understand role of craving in addictions
Just-published research led by a psychologist at the University of Georgia shows that behavioral economic analysis may lead to an improved understanding of craving for alcohol and other drugs. This method of studying how craving alters the way a person values a drug is fairly new, but according to the study, it may well help assess cravings more accurately and contribute to identifying more effective ways to defeat addictions.
GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market
Gold Standard Diagnostics, Inc. a leading supplier of products and services to the medical diagnostic industry today announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the U.S. Market. Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, sepsis. GSD will initially focus on distribution of Homocysteine, but also gains access to distribute Axis-Shield's other key products such as Anti-CCP.